INIS
thrombin
100%
proteins
73%
women
71%
estrogens
71%
risks
41%
evaluation
40%
reviews
33%
comparative evaluations
32%
sensitivity
28%
laboratories
26%
patients
26%
receptors
24%
hormones
23%
standardization
20%
hemostatics
19%
mutations
18%
pregnancy
16%
performance
16%
testing
16%
data
15%
symptoms
15%
breasts
14%
range
14%
cancer
13%
therapy
12%
coronaviruses
12%
lipids
12%
interlaboratory comparisons
12%
metabolism
12%
thrombosis
12%
globulins
12%
men
12%
menopause
12%
tamoxifen
12%
diseases
12%
bones
12%
antibodies
12%
screening
11%
safety
11%
steroids
9%
estradiol
9%
carbohydrates
9%
immunity
9%
progestin
8%
values
8%
guidelines
8%
anticoagulants
8%
automation
7%
membranes
7%
detection
6%
concentration
6%
inhibition
6%
populations
6%
doses
6%
capacity
6%
defects
6%
applications
6%
endometrium
6%
global analysis
6%
wave forms
6%
sex
6%
in vitro
6%
fetuses
6%
delivery
6%
blood
6%
peaks
5%
liver
5%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombin
61%
Oral Contraceptive Agent
46%
Activated Protein C Resistance
41%
Estetrol
25%
Venous Thromboembolism
25%
Activated Protein C
22%
Ethinylestradiol
19%
Hemostatic Agent
19%
Blood Stasis
18%
APC
16%
Drospirenone
13%
Oral Contraceptive
13%
Bleeding
13%
Levonorgestrel
12%
Menopausal Syndrome
12%
Estrogen Receptor Positive Breast Cancer
12%
Observational Study
12%
Tamoxifen
12%
Disproportionality Analysis
12%
Infection
12%
SARS Coronavirus
12%
Neutralizing Antibody
12%
Estrogen Receptor
11%
Progestin
9%
Thrombosis
8%
Estrogen Derivative
7%
Diethylstilbestrol
6%
Placebo
6%
Thrombogenicity
5%
Breast Cancer
5%
Keyphrases
Sensitivity Ratio
16%
Combined Oral Contraceptives
14%
Natural Estrogens
13%
Drospirenone
13%
APC Resistance
12%
Global Coagulation Tests
12%
Randomized Double-blind Study
12%
Hypercoagulability
12%
Panel Review
12%
Oral Contraception
12%
Climacteric Symptoms
12%
Hemostasis Parameters
12%
Oral Contraceptives
12%
Bone Turnover
12%
Estrogen Receptor-positive Breast Cancer
12%
Childbearing Women
12%
Menopause Symptoms
12%
Breast Cancer
12%
Breast Cancer Patients
12%
Activated Protein C
12%
Literature Review Analysis
12%
Venous Thromboembolic Events
12%
EudraVigilance Database
12%
Disproportionality Analysis
12%
Ethinylestradiol
12%
Omicron Sub-lineages
12%
Estrogen Receptor
9%
Membrane Estrogen Receptor
8%
Nuclear Estrogen Receptor
8%
Factor V Leiden mutation
8%
Levonorgestrel
7%
Reporting Rate
7%
Endogenous Thrombin Potential
7%
Thrombin Generation Assay
7%
Activated Protein C Resistance
7%
Projet
6%
User Satisfaction
6%
High Users
6%